Fast Five Quiz: Depression and Cognition

Stephen Soreff, MD

Disclosures

December 31, 2019

MAOIs have broad efficacy in affective and anxiety disorders. Due to the risk for hypertensive crisis associated with these agents, however, patients on MAOIs must follow a low-tyramine diet.

Nonpharmacologic treatment for patients with depression and cognitive dysfunction is individualized and multimodal, and may include exercise, bariatric surgery or weight loss, cognitive-behavioral therapy, and psychoeducation.

SSRIs are first-line medications for late-onset depression. Research suggests that these agents may not be effective in treating cognitive dysfunction, however, especially executive function. In many cases, SSRIs not only lift patients out of depression but also make them more open to psychotherapy.

SNRIs may be particularly useful as first-line agents in patients with significant fatigue or pain syndromes associated with depression.

Learn more about the treatment of depression.

Access the American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder and The National Institute for Health and Care Excellence (NICE) Clinical Guideline – Depression in Adults: Recognition and Management.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....